PE20001034A1 - Desnaturalizantes para las sales aminas simpaticomimeticas - Google Patents

Desnaturalizantes para las sales aminas simpaticomimeticas

Info

Publication number
PE20001034A1
PE20001034A1 PE1999000908A PE00090899A PE20001034A1 PE 20001034 A1 PE20001034 A1 PE 20001034A1 PE 1999000908 A PE1999000908 A PE 1999000908A PE 00090899 A PE00090899 A PE 00090899A PE 20001034 A1 PE20001034 A1 PE 20001034A1
Authority
PE
Peru
Prior art keywords
inhibitor
compounds
sympathomimetic amine
water
polymers
Prior art date
Application number
PE1999000908A
Other languages
English (en)
Inventor
William Michael Nichols
William S Bess
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20001034A1 publication Critical patent/PE20001034A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)UNA SAL ACIDA DE UNA AMINA SIMPATICOMIMETICA TAL COMO CLORHIDRATO O SULFATO DE PSEUDOEFEDRINA, CLORHIDRATO DE EFEDRINA O DE FENILPROPANILAMINA; b)UN INHIBIDOR DE COMBINACION TAL COMO SALES DE METAL DE TRANSICION (CLORURO, OXIDO, SULFATO O GLUCONATO DE HIERRO, COBALTO, COBRE, MANGANESO, NIQUEL O ZINC) Y POLIMEROS AMINO EN FORMA DE SAL NEUTRALIZADA TAL COMO COPOLIMERO DE METIL, BUTIL O DIMETILAMINOETIL METACRILATO; c)UN INHIBIDOR DE REACCION TAL COMO COMPUESTOS DE POLIHIDROXI INSOLUBLES EN AGUA, POLIHIDROXI NO POLIMEROS SOLUBLES EN AGUA, COMPUESTOS DE ESTER SOLUBLES EN ESTER; d)UN INHIBIDOR DE SEPARACION TAL COMO COMPUESTOS DE CELULOSA SOLUBLE EN AGUA, GOMAS POLISACARIDAS, POLIMEROS DE OXIDO DE POLIETILENO, POLIMEROS DE ACIDO ACRILICO, ALMIDONES, SILICATOS DE ALUMINIO Y MAGNESIO; POLIVINILPIRROLIDONAS Y ARCILLAS; SE CARACTERIZA PORQUE EL INHIBIDOR DE COMBINACION, DE REACCION E INHIBIDOR DE SEPARACION SE PRESENTAN EN CANTIDADES SUFICIENTES PARA INTERFERIR CON EL AISLAMIENTO O CON LA CONVERSION DE DICHA AMINA SIMPATICOMIMETICA EN OTROS COMPUESTOS FARMACOLOGICAMENTE ACTIVOS TAL COMO METANFETAMINA, ANFETAMINA, METCATINONA, CATINONA; SIN ALTERAR SIGNIFICATIVAMENTE LA LIBERACION DE DICHA AMINA SIMPATICOMIMETICA DE LA COMPOSICION EN COMPARACION CON LA COMPOSICION DESNATURALIZADA
PE1999000908A 1998-09-10 1999-09-09 Desnaturalizantes para las sales aminas simpaticomimeticas PE20001034A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9971298P 1998-09-10 1998-09-10

Publications (1)

Publication Number Publication Date
PE20001034A1 true PE20001034A1 (es) 2000-10-18

Family

ID=22276270

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000908A PE20001034A1 (es) 1998-09-10 1999-09-09 Desnaturalizantes para las sales aminas simpaticomimeticas

Country Status (22)

Country Link
US (4) US6359011B1 (es)
EP (1) EP1112089A1 (es)
JP (1) JP2002524534A (es)
KR (1) KR20010075021A (es)
CN (1) CN1201822C (es)
AR (1) AR032730A1 (es)
AU (2) AU771194B2 (es)
BR (1) BR9913575A (es)
CA (1) CA2339354A1 (es)
CO (1) CO5280050A1 (es)
CR (1) CR6106A (es)
GT (1) GT199900148A (es)
HK (1) HK1039898A1 (es)
HN (1) HN1999000156A (es)
MY (1) MY117971A (es)
NZ (1) NZ510012A (es)
PA (1) PA8481601A1 (es)
PE (1) PE20001034A1 (es)
SV (1) SV1999000148A (es)
TW (1) TW550071B (es)
UY (1) UY25702A1 (es)
WO (1) WO2000015261A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.
CN1224423C (zh) * 2000-07-17 2005-10-26 山之内制药株式会社 改善口服吸收的医药组合物
EP1920763B2 (en) * 2000-11-30 2022-06-15 Vectura Limited Pharmaceutical compositions for inhalation
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050220877A1 (en) * 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004045037A1 (de) * 2004-09-15 2006-03-16 Basf Ag Pharmazeutische Darreichungsformen mit erschwerter Extrahierbarkeit eines Sympathomimetikums aus der Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE602006019320D1 (de) * 2006-01-19 2011-02-10 Dow Global Technologies Inc Biologisch wirksame zusammensetzung mit ethylcellulose
US9238073B2 (en) * 2006-04-12 2016-01-19 Wyeth Llc Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
EP2167049B1 (en) * 2007-06-04 2016-08-31 Shear/Kershman Laboratories, Inc. Tamper resistant lipid-based oral dosage form for opioid agonists
CA2731801C (en) * 2007-07-23 2013-11-26 Kingsway Pharmaceuticals Inc. Therapeutic formulations for the treatment of cold and flu-like symptoms
JP4879351B2 (ja) 2007-10-19 2012-02-22 大塚製薬株式会社 医薬固形製剤
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
AU2010300641B2 (en) * 2009-09-30 2016-03-17 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
KR20140053158A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
WO2013036567A2 (en) * 2011-09-07 2013-03-14 Johnson Brent A Methods, compositions, and compounds for the reduction of illegal methamphetamine production
WO2013089986A1 (en) * 2011-12-12 2013-06-20 Product And Technology Partners Llc Improved denaturants for sympathomimetic amines
WO2014022541A1 (en) * 2012-08-01 2014-02-06 Acura Pharmaceuticals, Inc. Stabilization of one-pot methamphetamine synthesis systems
JP5922851B2 (ja) 2012-11-30 2016-05-24 アキュラ・ファーマシューティカルズ・インコーポレーテッド 活性医薬成分の自己制御放出
NZ716482A (en) * 2013-07-03 2017-07-28 Acura Pharmaceuticals Inc Methods and compositions for deterring abuse
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017042325A1 (en) * 2015-09-10 2017-03-16 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
TW202002957A (zh) 2018-02-09 2020-01-16 德商歌林達有限公司 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169092A (en) 1963-09-26 1965-02-09 Richardson Merrell Inc Stabilization of amines by tartrazine and bisulfite
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3773920A (en) * 1971-07-14 1973-11-20 Nikken Chemicals Co Ltd Sustained release medicinal composition
GB1593261A (en) 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
RO68771A2 (ro) * 1976-08-25 1980-08-15 Intreprinderea De Medicamente,Ro Unguent antipruriginos si sicativ
SU1146046A1 (ru) 1983-11-11 1985-03-23 Центральный Ордена Ленина Институт Усовершенствования Врачей Состав дл ретракции десны
US4493827A (en) 1983-11-14 1985-01-15 Ronald Valle Method of inducing sleep
US4657757A (en) 1985-03-29 1987-04-14 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4894239A (en) 1987-06-02 1990-01-16 Takeda Chemical Industries, Ltd. Sustained-release preparation and production thereof
ZA904021B (en) 1989-11-24 1991-02-27 Van Der Linde Leon Slimming preparations
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
WO1994028870A1 (en) 1993-06-04 1994-12-22 Warner-Lambert Company Preparations containing silicon dioxide to improve the taste thereof
US5543405A (en) 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
AUPM814994A0 (en) 1994-09-14 1994-10-06 Sterling Winthrop Inc. Codeine-containing formulations
US5529783A (en) * 1994-12-19 1996-06-25 Mcneil-Ppc, Inc. Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
US5626878A (en) * 1995-01-10 1997-05-06 Warner Lambert Company Reduction of electrostatic forces between magnesium trisilicate adsorbates
EP0894010B1 (en) 1996-04-10 2003-07-02 Warner-Lambert Company LLC Denaturants for sympathomimetic amine salts
GT199900148A (es) * 1998-09-10 2001-02-28 Desnaturalizantes para las sales aminas simpaticomimeticas.

Also Published As

Publication number Publication date
HN1999000156A (es) 2003-08-01
WO2000015261A1 (en) 2000-03-23
HK1039898A1 (zh) 2002-05-17
US6359011B1 (en) 2002-03-19
CR6106A (es) 2003-12-05
PA8481601A1 (es) 2001-04-30
TW550071B (en) 2003-09-01
AU2004202702A1 (en) 2004-07-15
KR20010075021A (ko) 2001-08-09
AU2004202702B2 (en) 2007-11-22
CO5280050A1 (es) 2003-05-30
GT199900148A (es) 2001-02-28
MY117971A (en) 2004-08-30
US20050256194A1 (en) 2005-11-17
JP2002524534A (ja) 2002-08-06
CN1201822C (zh) 2005-05-18
AU771194B2 (en) 2004-03-18
US20020082304A1 (en) 2002-06-27
US20060216268A1 (en) 2006-09-28
CN1316911A (zh) 2001-10-10
NZ510012A (en) 2002-11-26
UY25702A1 (es) 1999-11-17
SV1999000148A (es) 2000-09-11
EP1112089A1 (en) 2001-07-04
BR9913575A (pt) 2001-05-22
AR032730A1 (es) 2003-11-26
AU5915799A (en) 2000-04-03
CA2339354A1 (en) 2000-03-23

Similar Documents

Publication Publication Date Title
PE20001034A1 (es) Desnaturalizantes para las sales aminas simpaticomimeticas
HK1043785A1 (zh) 可用作藥物試劑的烷基氨基酸衍生物
DOP2002000392A (es) Sales tartrato de 5,8,14 triazatetraciclo [10.3.1.024 0.4.9] hexadeca-2 (11), 3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas
IT1256761B (it) Inibitori a doppia attivita' biologica di no sintasi e cicloossigenasiprocedimento per la loro preparazione e composizioni terapeutiche che li contengono.
RS51213B (sr) Farmaceutski vaginalni gel koji sadrži tenofovir
WO2001060416A3 (en) Matrix metalloproteinase inhibitors as targeting components in diagnostic agents
NZ594589A (en) 3h-imidazo [4, 5 -c] pyridine- 6 -carboxamides as anti- inflammatory agents
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
WO2001012233A3 (en) Sustained release formulation of a peptide
WO2005054179A3 (en) Hydroxamic acid esters and pharmaceutical use thereof
WO2001064645A3 (en) Derivatives of quinoline as alpha-2 antagonists
GEP20104882B (en) Age inhibitors
WO2005123049A3 (en) A pharmaceutical composition for increasing the mitochondrial genesis
HRP20100504T1 (hr) 2-(4-cijanofenil)-6-hidroksilaminopirimidini koji inhibiraju hiv
DE602004026903D1 (de) P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält
HN2000000031A (es) Inhibidores de acido abierto y sales de dihidrolixilo de redustosa hmg-co-a.
HRPK20040372B3 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
WO2008102349A3 (en) Terbinafine formulation for iontophoresis
SE0102440D0 (sv) New compound
UA93529C2 (ru) Соли и смеси 9-оксоакридин-10-уксусной кислоты c 1-алкиламино-1-дезоксиполиолами
AR080127A1 (es) Inhibidores de la amida hidrolasa de acidos grasos, composiciones farmaceuticas y sus usos
EA201000701A1 (ru) 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465
AR044175A1 (es) Compuestos de cefemo
ATE378335T1 (de) Chirale fluorochinolizinon arginine salze
AR079299A1 (es) Mejora de los procesos para la preparacion de granulos solubles de las sales de los acidos carboxilicos que contienen piridina

Legal Events

Date Code Title Description
FC Refusal